Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autophagy

- PMLiVE

Moderna and Immatics announce oncology collaboration worth over $1.7bn

The agreement will focus on the development of bispecifics, cell therapies and cancer vaccines

- PMLiVE

IO Biotech announces new data supporting its therapeutic cancer vaccine

The vaccine showed promise when used in combination with Merck & Co’s Keytruda

- PMLiVE

NIHR awards £2.3m for AI study to improve radiotherapy for lung cancer

The AI tool is expected to help doctors plan each patient’s radiotherapy treatment

- PMLiVE

ICR study supports use of new radioactive treatment for advanced prostate cancer

Experts are calling for NICE to assess if the treatment should be made available on the NHS

- PMLiVE

Seagen and Nurix announce oncology partnership worth over $3.4bn

The collaboration will focus on advancing a new class of medicines for use in cancer

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

Novo Nordisk enters new research alliance for diabetes and cardiometabolic diseases

The collaboration will focus on advancing three programmes across the next three years

- PMLiVE

ICR study finds way to determine efficacy of experimental breast cancer drugs

The findings could speed up the development of targeted therapies for breast cancer

- PMLiVE

Medscape’s Virtual Patient Simulation Makes a Significant Impact on Real-World Treatment Selection for T2D

An analysis of data using Real-World Outcomes showed that a virtual patient simulation had a significant effect on real-world treatment selection for T2D. The paper, published in JMIR Medical Education,...

Medscape Education Global

- PMLiVE

New screening model shown to predict ten year breast cancer mortality risk

The risk-based screening model works to identify those at the highest risk of cancer

- PMLiVE

New blood test could one day be used to diagnose Parkinson’s disease

The discovery could potentially lead to the development of a definitive diagnostic test

- PMLiVE

International survey reveals varying effects of oral medicines for Parkinson’s

More than 65% of respondents reported variations in the effects of taking oral medications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links